Sosiho‑tang ameliorates cachexia‑related symptoms in mice bearing colon 26 adenocarcinoma by reducing systemic inflammation and muscle loss

Kim,Aeyung; Im,Minju; Ma,Jin Yeul

doi:10.3892/or.2015.4527

Sosiho‑tang ameliorates cachexia‑related symptoms in mice bearing colon 26 adenocarcinoma by reducing systemic inflammation and muscle loss

Authors:
- Aeyung Kim
- Minju Im
- Jin Yeul Ma
View Affiliations

Affiliations: Korean Medicine (KM) Application Center, Korea Institute of Oriental Medicine (KIOM), Dong‑gu, Daegu 701‑300, Republic of Korea
Published online on: December 28, 2015 https://doi.org/10.3892/or.2015.4527
Pages: 1841-1850

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cachexia accompanied by muscle wasting is a key determinant of poor prognosis in cancer patients and cancer‑related death. Previous studies have demonstrated that inflammatory cytokines such as interleukin‑6 (IL‑6), tumor necrosis factor‑α (TNF‑α), IL‑1 and interferon‑γ (IFN‑γ) secreted from host cells and tumor cells participate in skeletal muscle wasting followed by severe loss of body weight. Therefore, blockade of the inflammatory response is thought to be a logical target for pharmacological and nutritional interventions to preserve skeletal muscle mass under cachectic conditions. Sosiho‑tang (SO; Xiaocharihu‑tang in Chinese and Sho‑saiko‑to in Japanese) is an Oriental herbal medicine that has been used to treat chronic hepatic diseases and to control fever. In recent studies, SO inhibited the production of inflammatory cytokines in lipopolysaccharide (LPS)‑stimulated macrophages, prevented thrombus formation and suppressed cancer progression. However, the anti‑cachectic activity of SO in tumor‑bearing mice has not yet been examined. In the present study, we characterized the effect of SO administration on cancer‑induced cachexia in CT‑26‑bearing mice, and elucidated the anti‑cachectic mechanisms. Daily oral administration of SO at doses of 50 and 100 mg/kg to CT‑26‑bearing mice significantly retarded tumor growth and prevented the loss of final body weight, carcass weight, heart weight, gastrocnemius muscle, and epididymal fat, compared with saline‑treated control mice. In addition, serum IL‑6 levels elevated by cancer were decreased by SO administration. In the J774A.1 macrophage cell line, SO efficiently suppressed LPS‑mediated increases in inducible nitric oxide synthase (iNOS) expression, nitric oxide (NO), and procachectic inflammatory cytokine production through inhibition of nuclear factor‑κB (NF‑κB) and p38 activation. In addition, SO attenuated muscle atrophy caused by cancer cells by affecting myoblast proliferation and differentiation, and C2C12 myotube wasting. Taken together, these results suggest that SO is a safe and useful anti‑cachectic therapy for cancer patients with severe weight loss.

View Figures

View References

1	Fearon KC, Voss AC and Hustead DS; Cancer Cachexia Study Group: Definition of cancer cachexia: Effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr. 83:1345–1350. 2006.PubMed/NCBI
2	Tazi E and Errihani H: Treatment of cachexia in oncology. Indian J Palliat Care. 16:129–137. 2010.
3	Aoyagi T, Terracina KP, Raza A, Matsubara H and Takabe K: Cancer cachexia, mechanism and treatment. World J Gastrointest Oncol. 7:17–29. 2015.PubMed/NCBI
4	Ozola Zalite I, Zykus R, Francisco Gonzalez M, Saygili F, Pukitis A, Gaujoux S, Charnley RM and Lyadov V: Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: A systematic review. Pancreatology. 15:19–24. 2015. View Article : Google Scholar
5	Grabiec K, Burchert M, Milewska M, Błaszczyk M and Grzelkowska-Kowalczyk K: Systemic and local mechanisms leading to cachexia in cancer. Postepy hig Med Dosw (Online). 67:1397–1409. 2013.In Polish. View Article : Google Scholar
6	Onesti JK and Guttridge DC: Inflammation based regulation of cancer cachexia. BioMed Res Int. 2014:1684072014. View Article : Google Scholar : PubMed/NCBI
7	Tamura S, Ouchi KF, Mori K, Endo M, Matsumoto T, Eda H, Tanaka Y, Ishitsuka H, Tokita H and Yamaguchi K: Involvement of human interleukin 6 in experimental cachexia induced by a human uterine cervical carcinoma xenograft. Clin Cancer Res. 1:1353–1358. 1995.PubMed/NCBI
8	Enomoto A, Rho MC, Fukami A, hiraku O, Komiyama K and hayashi M: Suppression of cancer cachexia by 20S,21-epoxy-resi bufogenin-3-acetate-a novel nonpeptide IL-6 receptor antagonist. Biochem Biophys Res Commun. 323:1096–1102. 2004. View Article : Google Scholar : PubMed/NCBI
9	Ando K, Takahashi F, Kato M, Kaneko N, Doi T, Ohe Y, Koizumi F, Nishio K and Takahashi K: Tocilizumab, a proposed therapy for the cachexia of Interleukin6-expressing lung cancer. PLoS One. 9:e1024362014. View Article : Google Scholar : PubMed/NCBI
10	Madeddu C, Macciò A, Panzone F, Tanca FM and Mantovani G: Medroxyprogesterone acetate in the management of cancer cachexia. Expert Opin Pharmacother. 10:1359–1366. 2009. View Article : Google Scholar : PubMed/NCBI
11	Mantovani G, Macciò A, Lai P, Massa E, Ghiani M and Santona MC: Cytokine involvement in cancer anorexia/cachexia: Role of megestrol acetate and medroxyprogesterone acetate on cytokine downregulation and improvement of clinical symptoms. Crit Rev Oncog. 9:99–106. 1998. View Article : Google Scholar
12	Inui A: Cancer anorexia-cachexia syndrome: Current issues in research and management. CA Cancer J Clin. 52:72–91. 2002. View Article : Google Scholar : PubMed/NCBI
13	Lee JK, Kim JH and Shin HK: Therapeutic effects of the oriental herbal medicine Sho-saiko-to on liver cirrhosis and carcinoma. Hepatol Res. 41:825–837. 2011. View Article : Google Scholar : PubMed/NCBI
14	Shimizu I: Sho-saiko-to: Japanese herbal medicine for protection against hepatic fibrosis and carcinoma. J Gastroenterol Hepatol. 15:D84–D90. 2000. View Article : Google Scholar : PubMed/NCBI
15	Mizushima Y, Kashii T, Tokimitsu Y and Kobayashi M: Cytotoxic effect of herbal medicine Sho-saiko-to on human lung-cancer cell-lines in vitro. Oncol Rep. 2:91–94. 1995.PubMed/NCBI
16	Yano H, Mizoguchi A, Fukuda K, Haramaki M, Ogasawara S, Momosaki S and Kojiro M: The herbal medicine Sho-saiko-to inhibits proliferation of cancer cell lines by inducing apoptosis and arrest at the G0/G1 phase. Cancer Res. 54:448–454. 1994.PubMed/NCBI
17	Oh YC, Cho WK, Jeong YH, Im GY, Lee KJ, Yang HJ and Ma JY: Anti-inflammatory effect of Sosihotang via inhibition of nuclear factor-κB and mitogen-activated protein kinases signaling pathways in lipopolysaccharide-stimulated RAW 264.7 macrophage cells. Food Chem Toxicol. 53:343–351. 2013. View Article : Google Scholar
18	Barton BE: IL-6-like cytokines and cancer cachexia: Consequences of chronic inflammation. Immunol Res. 23:41–58. 2001. View Article : Google Scholar : PubMed/NCBI
19	MacDonald N: Cancer cachexia and targeting chronic inflammation: A unified approach to cancer treatment and palliative/supportive care. J Support Oncol. 5:157–162. 2007.PubMed/NCBI
20	Deans C and Wigmore SJ: Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care. 8:265–269. 2005. View Article : Google Scholar : PubMed/NCBI
21	Bonetto A, Aydogdu T, Kunzevitzky N, Guttridge DC, Khuri S, Koniaris LG and Zimmers TA: STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS One. 6:e225382011. View Article : Google Scholar : PubMed/NCBI
22	Lokireddy S, Wijesoma IW, Bonala S, Wei M, Sze SK, McFarlane C, Kambadur R and Sharma M: Myostatin is a novel tumoral factor that induces cancer cachexia. Biochem J. 446:23–36. 2012. View Article : Google Scholar : PubMed/NCBI
23	Costelli P, Muscaritoli M, Bonetto A, Penna F, Reffo P, Bossola M, Bonelli G, Doglietto GB, Baccino FM and Rossi Fanelli F: Muscle myostatin signalling is enhanced in experimental cancer cachexia. Eur J Clin Invest. 38:531–538. 2008. View Article : Google Scholar : PubMed/NCBI
24	Jespersen J, Kjaer M and Schjerling P: The possible role of myostatin in skeletal muscle atrophy and cachexia. Scand J Med Sci Sports. 16:74–82. 2006. View Article : Google Scholar : PubMed/NCBI
25	Langen RC, Schols AM, Kelders MC, Wouters EF and Janssen-Heininger YM: Inflammatory cytokines inhibit myogenic differentiation through activation of nuclear factor-kappaB. FASEB J. 15:1169–1180. 2001. View Article : Google Scholar : PubMed/NCBI
26	Donohoe CL, Ryan AM and Reynolds JV: Cancer cachexia: Mechanisms and clinical implications. Gastroenterol Res Pract. 2011:6014342011. View Article : Google Scholar : PubMed/NCBI
27	Fujitsuka N, Asakawa A, Amitani H, Hattori T and Inui A: Efficacy of ghrelin in cancer cachexia: Clinical trials and a novel treatment by Rikkunshito. Crit Rev Oncog. 17:277–284. 2012. View Article : Google Scholar : PubMed/NCBI
28	Fujitsuka N and Uezono Y: Rikkunshito, a ghrelin potentiator, ameliorates anorexia-cachexia syndrome. Front Pharmacol. 5:2712014. View Article : Google Scholar : PubMed/NCBI
29	Yae S, Takahashi F, Yae T, Yamaguchi T, Tsukada R, Koike K, Minakata K, Murakami A, Nurwidya F, Kato M, et al: Hochuekkito (TJ-41), a kampo formula, ameliorates cachexia induced by colon 26 adenocarcinoma in mice. Evid Based Complement Alternat Med. 2012:9769262012. View Article : Google Scholar
30	Choi YK, Jung KY, Woo SM, Yun YJ, Jun CY, Park JH, Shin YC, Cho SG and Ko SG: Effect of Sipjeondaebo-tang on cancer-induced anorexia and cachexia in CT-26 tumor-bearing mice. Mediators Inflamm. 2014:7365632014. View Article : Google Scholar : PubMed/NCBI
31	Iizuka N, Miyamoto K, hazama S, Yoshino S, Yoshimura K, Okita K, Fukumoto T, Yamamoto S, Tangoku A and Oka M: Anticachectic effects of Coptidis rhizoma, an anti-inflammatory herb, on esophageal cancer cells that produce interleukin 6. Cancer Lett. 158:35–41. 2000. View Article : Google Scholar : PubMed/NCBI
32	Camargo CA, da Silva ME, da Silva RA, Justo GZ, Gomes-Marcondes MC and Aoyama H: Inhibition of tumor growth by quercetin with increase of survival and prevention of cachexia in Walker 256 tumor-bearing rats. Biochem Biophys Res Commun. 406:638–642. 2011. View Article : Google Scholar : PubMed/NCBI
33	Kim HM, Kim YY, Moon HS, Lee EH, Moon SJ and An NH: Inhibitory effect of anaphylactic reaction of Sosiho-Tang. Immunopharmacol Immunotoxicol. 20:567–578. 1998. View Article : Google Scholar : PubMed/NCBI
34	Lee JJ, Kim T, Cho WK and Ma JY: Antithrombotic and anti-platelet activities of Soshiho-tang extract. BMC Complement Altern Med. 13:1372013. View Article : Google Scholar
35	Su GY, Yang JY, Wang F, Xiong ZL, Hou Y, Zhang K, Song C, Ma J, Song SJ, Teng HF, et al: Xiaochaihutang prevents depressive-like behaviour in rodents by enhancing the serotonergic system. J Pharm Pharmacol. 66:823–834. 2014.